uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Defense World Staff on Feb 13th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $58.3333.

A number of brokerages have recently issued reports on QURE. Chardan Capital reiterated a “buy” rating and set a $53.00 target price on shares of uniQure in a research report on Thursday, December 4th. Mizuho dropped their price objective on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, December 8th. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a research report on Wednesday, January 14th. Finally, William Blair restated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th.

Check Out Our Latest Analysis on QURE

uniQure Price Performance

Shares of QURE stock opened at $22.37 on Friday. The stock’s fifty day moving average is $23.39 and its 200-day moving average is $28.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The stock has a market capitalization of $1.39 billion, a PE ratio of -5.10 and a beta of 0.66. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50.

uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. Equities research analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

Neutral Sentiment: Profile/coverage unrelated to the litigation but included in the feed (may be ignored by most investors). Sarah Tabrizi
Negative Sentiment: Kessler Topaz has filed a securities‑fraud class action against uniQure on behalf of investors who bought shares between Sept. 24 and Oct. 31, 2025. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) – Contact Kessler Topaz Meltzer & Check, LLP
Negative Sentiment: Multiple firms are soliciting lead‑plaintiff applicants and reminding investors of an April 13, 2026 deadline to join cases tied to the Sept.‑Oct. 2025 class period — signaling coordination of litigation activity. Example reminder from ClaimsFiler. uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. – QURE
Negative Sentiment: Holzer & Holzer and other firms allege uniQure made false/misleading statements and failed to disclose material issues — specifically that the pivotal study design and comparisons to ENROLL‑HD were not fully FDA‑approved and a BLA delay was likely. INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of uniQure N.V. (QURE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Negative Sentiment: Bloomberg Law and others report investor suits specifically over the delayed Huntington’s drug application — media coverage increases visibility and may accelerate selling pressure. UniQure Investor Sues Over Delayed Huntington’s Drug Application
Negative Sentiment: Multiple additional plaintiff firms (Rosen, Faruqi, Bernstein Liebhard, Berger Montague, Schall, etc.) have announced investigations or filings — the sheer number of firms increases probability of consolidated litigation and potential legal exposure. Example: Faruqi deadline notice. QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Insider Transactions at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. The trade was a 23.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares in the company, valued at $796,260.04. This trade represents a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of the business. Private Trust Co. NA acquired a new position in shares of uniQure in the 3rd quarter valued at $28,000. Jones Financial Companies Lllp lifted its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the period. CIBC Private Wealth Group LLC acquired a new position in uniQure in the third quarter valued at about $50,000. Torren Management LLC bought a new position in uniQure during the fourth quarter worth about $28,000. Finally, FNY Investment Advisers LLC grew its position in shares of uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.